Author: admin

The below Parliamentary question was asked by Andrew Percy on 2016-03-24.

To ask the Secretary of State for Health, how much the NHS spent on treating people with inflammatory bowel disease in (a) the last 12 months and (b) each of the last five financial years.

Jane Ellison

The information is not available in the format requested.

Such information as is available on the cost to the National Health Service of treating inflammatory bowel disease is from reference costs, which are the average unit cost to NHS hospital trusts of providing defined services to patients in a given financial year. Reference costs for acute care are collected by Healthcare Resource Group (HRG), a secondary classification system which groups similar treatments that use similar resources. Reference costs are published annually, most recently for 2014-15.

The following table reflects the costs of treating patients who are admitted to hospital and does not include the treatment of inflammatory bowel disease in outpatient or other settings outside of hospital. The costs are not comparable between years because of changes to the HRG design and to the underlying primary classification system for diseases.

Estimated total costs (£millions) to NHS hospitals of treating inflammatory bowel disease, 2010-11 to 2014-15

	2010-11	2011-12	2012-13	2013-14	2014-15
Inflammatory bowel disease	207.3	147.1	73.0	78.8	82.9
Paediatric inflammatory bowel disease	12.1	8.4	9.7	10.6	10.9
Total	219.4	155.5	82.6	89.5	93.8

Source: Reference costs, Department of Health

Notes:

1. For each HRG or other currency in the reference cost collection, NHS hospital trusts submit a unit cost and amount of activity undertaken.
2. Costs are not comparable between years:
   1. changes to the HRG design in 2011-12 resulted in the removal of HRGs specific to procedures for inflammatory bowel disease. These costs are included in other HRGs and are no longer separately identifiable.
   2. revised clinical coding guidance introduced in 2012-13 with the International Classification of Diseases 10th revision (ICD-10), fourth edition, resulted in the transfer of significant activity (and therefore costs) associated with infectious gastroenteritis and colitis to other HRGs.
3. The following HRGs are included in the table:

2010-11

FZ37F Inflammatory Bowel Disease with length of stay 1 day or less

FZ37G Inflammatory Bowel Disease with length of stay 2 days or more with Major Complications and Comorbidities (CC) with Interventions

FZ37H Inflammatory Bowel Disease with length of stay 2 days or more with Major CC without Interventions

FZ37I Inflammatory Bowel Disease with length of stay 2 days or more without Major CC with Interventions

FZ37J Inflammatory Bowel Disease with length of stay 2 days or more without Major CC without Interventions

FZ14Z Complex Procedures for Inflammatory Bowel Disease

FZ15Z Major Procedures for Inflammatory Bowel Disease

FZ28A Endoscopic or Intermediate Procedures for Inflammatory Bowel Disease 19 years and over with CC

FZ28B Endoscopic or Intermediate Procedures for Inflammatory Bowel Disease 19 years and over without CC

FZ28C Endoscopic or Intermediate Procedures for Inflammatory Bowel Disease 18 years and under

PA27Z Inflammatory Bowel Disease

2011-12

FZ37F Inflammatory Bowel Disease with length of stay 1 day or less

FZ37G Inflammatory Bowel Disease with length of stay 2 days or more with Major CC with Interventions

FZ37H Inflammatory Bowel Disease with length of stay 2 days or more with Major CC without Interventions

FZ37I Inflammatory Bowel Disease with length of stay 2 days or more without Major CC with Interventions

FZ37J Inflammatory Bowel Disease with length of stay 2 days or more without Major CC without Interventions

PA27Z Inflammatory Bowel Disease

2012-13

FZ37K Inflammatory Bowel Disease with Multiple Interventions, with CC Score 3+

FZ37L Inflammatory Bowel Disease with Multiple Interventions, with CC Score 0-2

FZ37M Inflammatory Bowel Disease with Single Intervention, with CC Score 4+

FZ37N Inflammatory Bowel Disease with Single Intervention, with CC Score 0-3

FZ37P Inflammatory Bowel Disease without Interventions, with CC Score 5+

FZ37Q Inflammatory Bowel Disease without Interventions, with CC Score 3-4

FZ37R Inflammatory Bowel Disease without Interventions, with CC Score 1-2

FZ37S Inflammatory Bowel Disease without Interventions, with CC Score 0

PA27Z Inflammatory Bowel Disease

2013-14 and 2014-15

FZ37K Inflammatory Bowel Disease with Multiple Interventions, with CC Score 3+

FZ37L Inflammatory Bowel Disease with Multiple Interventions, with CC Score 0-2

FZ37M Inflammatory Bowel Disease with Single Intervention, with CC Score 4+

FZ37N Inflammatory Bowel Disease with Single Intervention, with CC Score 0-3

FZ37P Inflammatory Bowel Disease without Interventions, with CC Score 5+

FZ37Q Inflammatory Bowel Disease without Interventions, with CC Score 3-4

FZ37R Inflammatory Bowel Disease without Interventions, with CC Score 1-2

FZ37S Inflammatory Bowel Disease without Interventions, with CC Score 0

PF27A Paediatric Inflammatory Bowel Disease with CC Score 1+

PF27B Paediatric Inflammatory Bowel Disease with CC Score 0

The below Parliamentary question was asked by Andrew Percy on 2016-03-24.

To ask the Secretary of State for Health, what steps his Department is taking to ensure that every patient with inflammatory bowel disease (IBD) is recorded on (a) a local searchable database and (b) the UK registry for IBD patients.

Jane Ellison

The IBD (inflammatory bowel disease) Registry provides a United Kingdom-wide repository of anonymised IBD adult and paediatric patient data for prospective audit and research purposes. Patients must consent for their data to be added to the registry. The Healthcare Quality Improvement Partnership (HQIP) has allocated transitional funding this year to incorporate IBD audit data collection into the IBD Registry, providing an enhanced system for data capture and quality improvement that will be available to every hospital in the UK. This will allow the entry of data locally and support service improvement. Initially the focus will be for IBD patients receiving biologic treatments, but the system will address other key aspects of IBD care in the future.

The second step of data collection will be to focus on new patients with IBD to begin to understand the incidence of IBD in the UK. This picture will build up over a number of years and be dependent on the engagement of clinicians.

No specific assessment of the potential effects on healthcare due to the introduction of a registry of patients with IBD in England has been made. However, the data provided through the register can support National Health Service services in areas such as the assessment of local IBD populations as well as in measuring incidence and outcomes with services in other parts of the UK.

Although there is no direct Department funding, HQIP have given £290,000 for a year’s transition funding to join the audit data with the registry.

The National Institute for Health and Care Excellence (NICE) recommends faecal calprotectin testing as an option to help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and non-inflammatory bowel diseases, such as irritable bowel syndrome.

The NICE IBD Quality Standard states that general practitioners (GP) and GP practices should ensure that testing is offered and clinical commissioning groups should ensure the diagnostic services are in place to support this.

The below Parliamentary question was asked by Andrew Percy on 2016-03-24.

To ask the Secretary of State for Health, whether his Department plans to use the inflammatory bowel disease (IBD) registry to get an accurate number of people living with IBD.

Jane Ellison

The IBD (inflammatory bowel disease) Registry provides a United Kingdom-wide repository of anonymised IBD adult and paediatric patient data for prospective audit and research purposes. Patients must consent for their data to be added to the registry. The Healthcare Quality Improvement Partnership (HQIP) has allocated transitional funding this year to incorporate IBD audit data collection into the IBD Registry, providing an enhanced system for data capture and quality improvement that will be available to every hospital in the UK. This will allow the entry of data locally and support service improvement. Initially the focus will be for IBD patients receiving biologic treatments, but the system will address other key aspects of IBD care in the future.

The second step of data collection will be to focus on new patients with IBD to begin to understand the incidence of IBD in the UK. This picture will build up over a number of years and be dependent on the engagement of clinicians.

No specific assessment of the potential effects on healthcare due to the introduction of a registry of patients with IBD in England has been made. However, the data provided through the register can support National Health Service services in areas such as the assessment of local IBD populations as well as in measuring incidence and outcomes with services in other parts of the UK.

Although there is no direct Department funding, HQIP have given £290,000 for a year’s transition funding to join the audit data with the registry.

The National Institute for Health and Care Excellence (NICE) recommends faecal calprotectin testing as an option to help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and non-inflammatory bowel diseases, such as irritable bowel syndrome.

The NICE IBD Quality Standard states that general practitioners (GP) and GP practices should ensure that testing is offered and clinical commissioning groups should ensure the diagnostic services are in place to support this.

The below Parliamentary question was asked by Andrew Percy on 2016-03-24.

To ask the Secretary of State for Health, what assessment he has made of the potential effects on healthcare of the introduction of a registry of patients with inflammatory bowel disease in England; and what support his Department has provided for that registry.

Jane Ellison

The IBD (inflammatory bowel disease) Registry provides a United Kingdom-wide repository of anonymised IBD adult and paediatric patient data for prospective audit and research purposes. Patients must consent for their data to be added to the registry. The Healthcare Quality Improvement Partnership (HQIP) has allocated transitional funding this year to incorporate IBD audit data collection into the IBD Registry, providing an enhanced system for data capture and quality improvement that will be available to every hospital in the UK. This will allow the entry of data locally and support service improvement. Initially the focus will be for IBD patients receiving biologic treatments, but the system will address other key aspects of IBD care in the future.

The second step of data collection will be to focus on new patients with IBD to begin to understand the incidence of IBD in the UK. This picture will build up over a number of years and be dependent on the engagement of clinicians.

No specific assessment of the potential effects on healthcare due to the introduction of a registry of patients with IBD in England has been made. However, the data provided through the register can support National Health Service services in areas such as the assessment of local IBD populations as well as in measuring incidence and outcomes with services in other parts of the UK.

Although there is no direct Department funding, HQIP have given £290,000 for a year’s transition funding to join the audit data with the registry.

The National Institute for Health and Care Excellence (NICE) recommends faecal calprotectin testing as an option to help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and non-inflammatory bowel diseases, such as irritable bowel syndrome.

The NICE IBD Quality Standard states that general practitioners (GP) and GP practices should ensure that testing is offered and clinical commissioning groups should ensure the diagnostic services are in place to support this.